



Real-World Stereoacuity Outcomes of a Binocular, Dual-Mechanism Therapy for Amblyopia: Results from the PUPiL Registry

Brenda L. Bohnsack, MD, PhD

Fatema Ghasia, MD

Eric D. Gaier, MD, PhD

Shelley Hancock




Disclosures

- Brenda L. Bohnsack, MD, PHD: Luminopia (Consultant)
- Fatema Ghasia: None
- Eric D. Gaier: Luminopia (Shareholder, Patents/Royalty)
- Shelley Hancock: Luminopia (Employee)


Luminopia



- FDA-cleared for treating amblyopia in 4 to <13 years old children
- Digital therapeutic software delivered with a head-mounted display
- Patients Using Prescription Luminopia (PUPiL) Registry (IRB approved) established to study therapeutic potential beyond phase 3 trial (NCT06429280)
- Real-world use of Luminopia (2000 patients over 3 years)
- Outcomes, treatment duration, dose response, rebound effect




PUPiL Registry


- ≥ 12 weeks of Luminopia
- Completed treatment and had stereoacuity at baseline and final follow-up*
- Demographics: Age, Insurance Type, Gender, Amblyopia Type/Severity
- Exam findings: BCVA and stereoacuity at baseline and final follow-up
- Stereoacuity:
 - Fine: ≤ 2.1 Log Arcsec  
 - Gross: > 2.1 Log Arcsec to 3.5 Log Arcs 
 - No detectable: > 3.5 Log Arcsec

* Data submitted up to 3/4/25 included in this analysis


109 Children, Mean Initial Age 7.5 ± 2.5 yrs




Age




Insurance




Gender



Prior Treatment




Amblyopia Severity



Amblyopia Type




Luminopia Improved BCVA


109 Children, Treatment 8.4 ± 4.4 Months



Stereoacuity Change With Luminopia

109 Children, Treatment 8.4 ± 4.4 Months








Stereoacuity Change With Luminopia

79 Children With Gross or No Detectable Stereoacuity

LogMAR BCVA Change







Stereoacuity Change







Stereoacuity and Amblyopia Severity

79 Children With Gross or No Detectable Stereoacuity



Stereoacuity and Amblyopia Type

79 Children With Gross or No Detectable Stereoacuity



PUPiL Registry: Safety & Limitations

- Safety: Headaches in 3 patients (2.8%)
- Limitations:
 - Retrospective registry
 - 14 sites across US - may not represent all patients on treatment
 - No standardized method of BCVA or stereoacuity collection
 - Data queries are at specific time intervals which may not correspond with visits



Thank You For Your Attention!

